

# SWISS BIOTECH DAY 2018

The leading Life Sciences Conference in Switzerland and Annual General Assembly of the Swiss Biotech Association



### Conference Guide

3 MAY 2018

**Basel Congress Center** 

Organised by:



**BIOCOM AG** 

Poture: @ Rynacher/ https://comnons.wikineda.org/wiki/Tie:Basilisk\_Wetsteint cke.JPG (CC BYSA.3.0); GNU Free Documentation License

# Programme

09:00	Exhibition and Partnering throughout the Day	Exhibition Area	
10:00	General Assembly of the Swiss Biotech Association (by invitation only)	Room Shanghai 1+2	
Plenar	y Session	Room Sydney	
Moderation: Monika Jones			
11:00	Welcome Address  Dominik Escher, President, Swiss Biotech Association  Michael Altorfer, CEO, Swiss Biotech Association		
11:10	Keynote I: Creating a Culture of Innovation at Novartis Vasant Narasimhan, CEO, Novartis AG		
11:30	Keynote II: Glycart Biotechnology to Roche Innovation Center Zurich: a Journey in Cancer Immunotherapy R&D Pablo Umaña, Head Cancer Immunotherapy Discovery & LMR Zurich, Roche Glycart AG		
11:50	Keynote III: Facing the Future – Rentschler Biopharma SE Frank Mathias, CEO, Rentschler Biopharma SE		
12:10	Presentation of the Swiss Biotech Report Jürg Zürcher, Partner, Ernst & Young AG		
12:30	Lunch – hosted by Cog/lite		





Analys	t & Investor Track	Room Shanghai 1+2		
Moderation: Bob Pooler, valuationLAB AG				
13:30	Santhera Pharmaceuticals AG, Thomas Meier, CEO			
13:50	Newron Pharmaceuticals S.p.A., Stefan Weber, CEO			
14:10	Addex Therapeutics Ltd., Tim Dyer, CEO			
14:30	Idorsia Pharmaceuticals Ltd, André Muller, CFO			
14:50	Molecular Partners, AG Patrick Amstutz, CEO			
15:10	InnoMedica Holding AG, Jonas Zeller, CFO			

Presented by





### International R&D Cooperation Forum with a Focus on UK

Room Shanghai 3

15:00 Switzerland and the UK leading the Way for international R&D: how to benefit from this Springboard?

Liv Minder, Director Investment Promotion, Switzerland Global Enterprise Noel McEvoy, Director, Department of International Trade Switzerland Christof Klöpper, Senior Project Manager, Switzerland Innovation

15:20 Case Study: a Unique Ecosystem for Successful International Collaboration in Oncology

Venkat Reddy, VP Global Head of Translational Sciences, Glenmark Pharmaceuticals Oliver Philippe, Head of Business Development & Corporate Relations, Biopôle Antoine Jourdan, Director, Switzerland Innovation Park Network West EPFL

15:50 Looking for Collaborations in Switzerland: UK Companies Pitch
Pharm-Olam, Pharmaron, Janssen Oncology, LifeArc, Antimicrobial Resistance
Centre, ARCINOVA

### 16:45 End of Track

Presented by



Emerg	ing Biotech Companies	Room Kairo 1+2
Moderation: Martin Heldt, VP & General Manager, IQVIA Switzerland		
13:30	IQVIA Company Overview Presentation Martin Heldt, VP & General Manager	
13:45	TOPADUR PHARMA AG, Reto Naef, CEO and founder	
13:55	Vaxxilon AG, Tom Monroe, CEO	
14:05	Therachon AG, Christian Meyer, CEO	
14:15	Heptares Therapeutics Zürich Ltd., Carlo Bertozzi, Director o	f Operations
14:25	Cellestia Biotech AG, Michael Bauer, CEO	
14:35	SynDermix AG, Dieter Hemmer, CEO	
14:45	Legacy Healthcare SA, Marcos Val, CFO	
14:55	CDR-Life AG, Christian Leisner, CEO	
15:05	IQVIA Presentation on Drug Development Strategy, Clinic Asset Valuation & Due Diligence Martin Heldt, VP & General Manager Tim Wintermantel, Head Real World Insights Services, Switze Max Rubin, Senior Principal, Strategy and Portfolio Analysis	•
15:30	DXC RT AG, Maëlle Garnier, Project Manager	
15:40	Lunaphore Technologies SA, Andrea Büchler, Finance & Bus Development Manager	iness
15:50	SimplicityBio SA, Matthew Hall, CEO and Co-founder	
16:00	Biognosys AG, Oliver Rinner, CEO	

16:10	SOPHiA GENETICS SA, Esteban Czwan, VP Business Development
16:20	certus molecular diagnostics ag, Tim Pfister, CFO
16:30	IQVIA Presentation on Commercialization Paolo Molinari, Head Commercial Effectiveness Services, Switzerland
16:45	Wrap-up and close







Fundir	Funding biotech companies – discuss with the experts  Room Dehli					
Moderation: Monika Jones						
13.30	Introduction					
13.50	Discuss with the Experts					
	Martin Rohrbach & Remko Van de Kreeke, KPMG AG (Auditors & Advisors)					
	Christian Fehr, SIX Swiss Exchange as Stock Exchange Expert					
	Richard Schindler, Zürcher Kantonalbank as Bank Expert					
	Dieter Gericke, Homburger AG as Law Expert					
	Dr. Markus Hosang, BioMedPartners as Investor Expert					
	Hazel Winchester, Basilea Pharmaceutica Ltd. as listed Con	npany Expert				
	Aitana Peire, Venture Valuation as Valuation Company Exper	t				
15:30	Wrap-up: Analysis of Survey & Discussion					

17:00–19:00 Exhibition Area

## Swiss Biotech Association's 20<sup>th</sup> Anniversary with Apéro riche & launch of the Swiss Biotech Success Stories Campaign

Swiss Biotech Association cordially invites you to join us for our 20<sup>th</sup> anniversary celebration and the launch of the Swiss Biotech Success Stories campaign. Embedded in Switzerland's leading biotechnology conference – the Swiss Biotech Day – this evening event will entertain you with an exclusive programme, honoring and celebrating significant contributions to Switzerland's biotech industry, accompanied by an apéro riche and plenty of room for networking.







# SWISS BIOTECH DAY 2019

The leading Life Sciences Conference in Switzerland and Annual General Assembly of the Swiss Biotech Association



Are you interested in having an exhibition booth, a company presentation in the afternoon tracks, your own private partnering forum, break sponsoring and much more at the next Swiss Biotech Day?


For more information about sponsor packages or simply participating in the Swiss Biotech Day 2019 on  $7^{\text{th}}$  May, please visit the BIOCOM stand no 2 on site or contact us via e-mail at marketing@biocom.de.

Organised by:



**BIOCOM AG** 





### **Exhibitors**

BIOCOM AG BIOCOM AG

BIOCOM is the leading communication and information company specialized on life sciences. Based on thorough analyses of the biotech, medtech and bioeconomy sectors in Europe, BIOCOM offers reports as well as customized consultancy services, surveys and research studies to clients. In communication services, clients receive everything from one source: conferences, videos, websites and brochures are not only designed, but also implemented and produced.

Booth 2

### **Becton Dickinson AG**



BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD helps customers enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. bd.com.

**Booth 16** 

### Biomapas Sàrl



Biomapas – a Full Service CRO. We are experienced in Clinical Trials, Regulatory Affairs, Medical Writing and Pharmacovigilance services. More than 17 years Biomapas supports Pharma, Biotech and Medtech companies in Europe, Russia, CIS and MENA regions. Our team has deep expertise in conducting clinical studies, leading medicinal products and medical devices to the market, providing life-cycle management and pharmaco-/materiovigilance services.

### Biopôle SA



Biopôle is a unique life sciences park hosting a vibrant community of industry players and research institutes, based in Lausanne, Switzerland. Biopôle offers a world-class combination of infrastructure, added value services, a life sciences incubator StartLab, over 134,000 sqm of living space and community engagement where partners can thrive and bring science to life. Oncology, immunology, personalized medicine, nutrition, medtech and digital health are our main focus.

### Biotechpharma UAB



Biotechpharma is a contract development and manufacturing organisation (CDMO). We perform cell line construction, cell banking, analytical development, process development and cGMP production. Our clients get highest service in our state-of-the-art facility. Biotechpharma produces microbially based recombinant proteins and mammalian cell culture-based monoclonal antibodies (mAb's) in up to 2000 L-batches.

**Booth 28** 

### BioTeZ Berlin-Buch GmbH



BioTeZ is a 1992 founded biotech company offering the following services: Assay Development, Conjugates & Labelling, Surface Functionalization & Coatings, DNA / RNA Synthesis including customized biomolecule modifications. BioTeZ is known for the products in the fields of Immuno Affinity Chromatography, Columns & Gels, Individual Reagents, Lateral Flow Test development, Human Proteases Expression & Activity tests, Drug-Target Efficiency Tests for PK & PD studies.

### **CES NV**



Quality and reliability are the two main key words in pharmaceutical industry. At CES, we understand your concerns and integrate them in every production step throughout the company from design and production phase to on-site activities. Our high quality equipment offers a flexible and reliable solution for cryogenic product stabilization. At CES, we are dedicated to the pharmaceutical and biotech industries and since 1988 we provide quality freezing & flexible solutions.

Booth 18

### **Collaborative Drug Discovery**



Collaborative Drug Discovery (CDD) provides an intuitive software suite extensively used by creative biologists and chemists working in academic, biotechnology and pharmaceutical settings. Their flagship product, CDD Vault, enables researchers to intuitively organize and analyze both biological study data and chemical structures, and to collaborate with partners through a straightforward web-interface. Learn more at www.collaborativedrug.com.

### DrM, Dr. Mueller AG



DrM, founded in 1982 by Dr. Hans Mueller, is specialized in Solid/Liquid Separation, Vibratory Mixing and Single-Use Technologies. Our products experience worldwide recognition in Fine & Specialty Chemicals, biopharmaceutical Up- and Downstream Processing, Food & Agrochemical and Flavors & Fragrances, to name a few. We are delighted to introduce this year our two new patents: FUNDABAC® Single-Use Multi-Cycle Filter and FUNDAMIX® Single-Use Vibratory Mixer. → www.drm.ch **Booth 22** 

### Haselmeier



Haselmeier Smart Drug Delivery: Medical Technology with Tradition. Innovative Injection Systems for the Future. Our goal is to make the world better for patients by creating a new generation of injection systems for subcutaneous self-administration. We develop and produce self-injection systems that dispense exact doses and that are easy to use. We are a strategic partner for our customers in the pharmaceutical and biotechnology market segments with innovative Drug Delivery Platforms. **Booth 24** 

### InnoMedica Holding AG



InnoMedica is a Swiss nanomedicine company developing and commercializing a liposomal drug delivery platform. The clinical trial application of the first product Talidox is under review by the Swiss authorities after having shown strong preclinical evidence in cancer therapy. The second pipeline product Talineuren uses the liposomal platform to deliver a neuro-stimulant substance to the brain and shows regenerative effects against Parkinson in preclinical studies.

Booth 9

### **IQVIA**



IQVIA (NYSE:IQV) is a leading global provider of information, innovative technology solutions and contract research services focused on helping healthcare clients find better solutions for patients. Especially for Emerging Biopharma Companies IQVIA offers a comprehensive set of flexible solutions. From defining the plan for your asset, to trial implementation, through launch and commercialization, IQVIA can help you find your path to success. To learn more visit www.iqvia.com. **Booth 17** | **Kairo 1+2** 

### JAG Jakob Ltd



JAG is a leading process technology company which designs and builds the most challenging and highly automated process plants for the pharmaceutical and biotech industries. Our plants are among the world's most efficient. Using the JAG PdiCS automation solution, we can fully automate even the largest and most challenging production processes in the pharmaceutical and biotech industry and provide for maximum productivity.

Booth 27

### **Kneat Solutions**



Kneat software enables an end-to-end paperless process for all Validations, Commissioning & Qualification, production execution and Quality document management. Kneat allows users to electronically create, approve & execute all testing, exceptions and approve final reports in a controlled FDA Part 11/ Eudralex Annex 11 compliant platform. Our Pharma/ Biotech clients report productivity improvements in excess of 100%, cost savings in excess of 50% and a higher compliance standard. **Booth 29** 

### **LSZYSN**



The Life Science Zurich Young Scientist Network (LSZYSN) is a group of currently 25 volunteer PhD students and post-docs mainly from the University of Zurich and ETH Zurich. Our goal is to bridge the gap between academia and industry. To achieve this, the LSZYSN is engaged in a wide range of activities aiming to build sustainable relationships with life sciences/healthcare companies and to provide a basis for young university graduates to get in touch with these companies.

Booth 1

### LYO-X GmbH



LYO-X is a Basel based company providing Systems Pharmacology and mathematical PK/PD modelling services for biotech companies. LYO-X's expertise are novel therapeutic formats: antibodies, bi-specifics, antibody-drug conjugates (ADCs), fusion proteins, peptides, gene therapies and siRNAs. LYO-X is one of the few providers worldwide in this nice domain and has been supporting over 70 companies globally in translating their highly innovative therapeutic molecules into patients.

### M+W Central Europe GmbH



M+W GROUP

M+W Central Europe GmbH, a subsidiary of the M+W Group, is one of the leading high technology engineering and construction companies for the life sciences industries. The portfolio includes individual as well as full-service solutions from concept and design up to the turnkey construction of production facilities, commissioning & hookup, qualification & validation and also technical facility management.

**Booth 26** 

### Microsynth AG

### Microsynth

Microsynth (founded in 1989) is a European leading company in the area of nucleic acid synthesis & analysis. The main activities are divided into following three business areas: 1. DNA/RNA oligonucleotide synthesis, 2. DNA/RNA analysis and sequencing, 3. Contract research/outsourcing. At its headquarter in Balgach, Switzerland Microsynth employs a staff of about 50 people. Microsynth has subsidiaries in Germany (Seqlab GmbH), Austria (Microsynth Austria GmbH) and Switzerland (ecogenics GmbH).

### MLM Medical Labs GmbH



MLM Medical Labs is a Central Laboratory dedicated exclusively to clinical trials. We offer full laboratory services, including a whole range of analytics: standard safety profiles, and analyses of biomarkers, drug compounds, metabolites and molecular diagnostic parameters. Our highly skilled 56-person team supports over 130 clinical studies at any given time. Internationally active in over 40 countries, including the U.S. and Eastern Europe, we are located in Moenchengladbach, near Duesseldorf.

### Morgan Sindall Professional Services AG

MORGAN SINDALL

Morgan Sindall is an integrated engineering provider of consulting, design, project management, asset life cycle management and beyond. Our extended experience in the biotech, pharma, fine chemicals and energy sectors make our know-how unique and enable us to provide our customers with fully-integrated, complete and tailored solutions. Our top-notch performance and one-stop-shop characteristics have made us a leading engineering partner in the D-A-CH Region.

Booth 19

### **PSI CRO AG**



PSI is a privately-owned, full-service clinical research organization (CRO) operating globally. PSI's global reach supports clinical trials across multiple countries and continents, and is known to be highly selective about the work that they pursue. With an exceptionally high repeat and referral business rate combined with minimal staff turnover, PSI is committed to being the best CRO in the world as measured by its customers and its employees.

Booth 7

### Rentschler Biopharma SE



Rentschler Biopharma SE is a leading CDMO for process development and manufacturing of biopharmaceuticals as well as formulation in Strategic Alliance with Leukocare AG and fill & finish with our Strategic Partner Rentschler Fill Solutions GmbH. Long-standing experience and excellence as a solution partner for our clients ensures Rentschler Biopharma's high quality standards. Rentschler Biopharma is an independent, family-owned company employing more than 800 people.

Booth 21 | Sydney

### **Swiss Group for Clinical Cancer Research**



The Swiss Group for Clinical Cancer Research (SAKK) has committed itself to conducting clinical cancer trials as a non-profit organization. It is our goal to investigate new cancer therapies and to improve existing tumor treatments, taking into account all available treatment options, in order to cure the disease or to prolong survival and improve life quality of patients suffering from cancer. SAKK is organized as a membership association.

**Booth 13** 

### **Swiss Biotech Association**



Since 1998 Swiss Biotech Association (SBA) represents the interests of the biotechnology industry. It is a highly-respected networking platform, supporting more than 200 members and the whole sector by improving framework conditions, encouraging investment and entrepreneurship, fostering networking, attracting talent, and disseminating the industry's value creation. The SBA partners with the Swiss life science clusters and manages Swiss Biotech<sup>TM</sup> – the global brand for the industry.

Booth 3

### Schmidt Versicherung Treuhand AG



We're among the very few broking firms in Switzerland experienced in handling life science companies – for example those involved in biotech, implants and pharmaceuticals. Working in close co-operation with specialised underwriters we provide tailormade solutions for our clients. As a result Schmidt Versicherungs Treuhand AG is well on the way to becoming one of the leading broking firms in the field.

Booth 25

### Socorex ISBA SA



Swiss manufacturer of precision liquid handling instruments: Electronic & manual micropipettes, repeater pipettes, bottle-top dispensers, electronic & manual pipette controllers, self-refilling syringes and consumables. Instruments operate under standards such as ISO 8655, GLP, GMP. Each instrument passes a strict quality control, attested by an individual QC certificate. Pipette lines bear the CE mark (IVD 98/79/CE conform). ISO 17025 accredited control laboratory.

### **Swiss Healthcare Licensing Group**



Swiss HLG is a group of passionate Senior Business Development Executives working together to serve those actively involved in BD&L and deal-making. The association is open to the international healthcare and life sciences industries and provides the richest possible environment to network, build strategic relationships, exchange ideas and to share experiences. Swiss HLG has about 170 members, has delivered 27 industry conferences and has an excellent reputation for quality.

Booth 4

### **TRIPLAN Ingenieur AG**



TRIPLAN accompanies Start-Up companies from lab scale to market thanks to our five decades of experience in comprehensive consulting services, laboratory design and engineering expertise as well as technologically leading CAD applications. We develop solutions that meet the highest technical and economical standards for the long term.

**Booth 14** 

### Wood Wood.

For more than 40 years, Wood (former Amec Foster Wheeler) has provided effective solutions to the life sciences industry. Whether you're a biotech start-up or a major pharmaceutical company, with a detailed understanding of our customers' business needs, Wood delivers customized solutions across an asset's entire life cycle. From planning, initial design, permitting and licensing through to construction and long-term asset support, Wood helps develop the best solutions for our customers' projects. **Booth 15** 

Disclaimer: All information on the participating companies was provided by the companies themselves. BIOCOM is not responsible for that content.

# Presenting Companies

### Addex Therapeutics Ltd.



Addex Therapeutics is pioneering discovery and development of an emerging class of oral small molecule drugs, called allosteric modulators, which can be exquisitely selective for their intended target and confer significant therapeutic advantages over conventional "orthosteric" small molecule or biological drugs. Founded in 2002, Addex is headquartered in Geneva and listed on the SIX Swiss Stock Exchange under the trading symbol ADXN.

14:10 | Shanghai 1+2

### **Biognosys AG**



Biognosys is the leading proteomics company offering innovative services and products for high content protein analysis. We are dedicated to transforming the life sciences with superior proteomics solutions based on cutting-edge mass spectrometry technology. We strive to be the company that provides the best possible solutions to support researchers in their protein analysis needs.

16:00 Kairo 1+2

### Cellestia Biotech AG



Cellestia is a privately-owned clinical stage company located in Basel and Lausanne, Switzerland, developing innovative first-in-class anti-cancer drugs originated from its unique discovery platform. Our clinical stage lead compound CB-103 is an oral small molecule protein-protein interaction inhibitor, acting as selective oncogene transcription factor inhibitor for therapy of NOTCH positive cancers. The development is accompanied by a diagnostic program for patient selection.

14:25 | Kairo 1+2

### certus molecular diagnostics ag



We provide molecular rapid tests for the reliable on-site detection of specific microbes. Our first available product identifies mycoplasma contaminations within 30min. Requiring just a few microliters of sample volume, a detection limit of 10 CFU/ml is reached. Based on the company's novel isothermal amplification and real-time detection method, a customized assay can be developed within a few weeks. Please feel free to contact us, we will find a tailored solution for you!

16:20 | Kairo 1+2

### **DXC RT AG**



Basel-based DXC RT is a biotech company offering a full R&D service in TCM and alpine plants with pilot scale-up. All our projects start with a clean sourcing and go through a gentle downstream processing to preserve plants' quality and power. By integrating health approach from both East and West, DXC RT gives birth to innovative concepts, technologies, high quality and contamination-free plant-derived ingredients for cosmetic, nutritional and pharmaceutical industries.

15:30 | Kairo 1+2

### Heptares Therapeutics Zürich Ltd.



Heptares Therapeutics Zurich is a recently established site of the clinical stage UK biotech company Heptares Therapeutics. The local subsidiary primarily focuses on enabling and visualising drug targets in complex with new potential medicines. Together with the teams in the UK we are developing a pipeline of proprietary molecules, and work in collaboration with major global pharmaceutical companies on small molecule and antibody programmes.

14:15 | Kairo 1+2

### Idorsia Pharmaceuticals Ltd



The purpose of Idorsia is to discover, develop and bring more, innovative medicines to patients. We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into one of Europe's leading biopharmaceutical companies, with a strong scientific core. Idorsia is specialized in the discovery and development of small molecules, to provide innovative therapeutic options.

14:30 | Shanghai 1+2

### Legacy Healthcare SA



Innovative R&D biopharma company in dermatology, immune-dermatology and oncology supportive care. It developed & patented a 1<sup>st</sup> botanical ingredient (Cellium) to derive 2 science-backed cosmetic products (anti-hair loss topical lotions), launched by Sanofi, Abbott and Nestle Skin Health. Following such proof of concept, resources were reinvested to additionally develop 3 botanical drugs (2004 FDA/EMA regulatory pathway) that today are in Pre-clinical, Ph II & Ph III.

14:45 | Kairo 1+2

### **Lunaphore Technologies SA**



Lunaphore is a Swiss company, building a fully automated fast tissue staining device. The core of the technology, a microfluidic chip, improves delivery of the reagents to the sample surface, showing more precise results as demonstrated through clinical studies. Thanks to the fluidic properties staining time can be reduced up to 20-fold, compared to conventional methods.

15:40 | Kairo 1+2

### Molecular Partners AG



Molecular Partners is a clinical-stage biopharmaceutical company working to advance modern medicine and significantly improve the management of serious diseases. We are developing a powerful new class of potent, specific and versatile small protein therapies called DARPin® therapeutics.

14:50 | Shanghai 1+2

### Newron Pharmaceuticals Ltd.



Newron (SIX: NWRN) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. In its pipeline: Xadago® (Adjunctive therapy in PD) commercialized by Newron's partners in the EU, Switzerland and US; sarizotan (Rett syndrome); ralfinamide (rare pain indications) and Evenamide (adjunctive therapy in schizophrenia and Clozapine TRS). www.newron.com

13:50 | Shanghai 1+2

### Santhera Pharmaceuticals AG



Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company with a portfolio of innovative medicines for rare neuro-ophthalmologic, neuromuscular and pulmonary diseases. Lead product Raxone® (idebenone) is marketed in Europe for Leber's hereditary optic neuropathy and in late Phase III for Duchenne muscular dystrophy. The pipeline includes omigapil for congenital muscular dystrophy and POL6014 for cystic fibrosis, both areas of high unmet medical need.

13:30 | Shanghai 1+2

### SimplicityBio SA



SimplicityBio serves pharmaceutical and diagnostic companies in their translational efforts. Its machine learning platform BOSS – Biomarker Optimisation Software System turns diverse data streams (omics, clinical, RWE, etc) into robust tailored models. BOSS provides value to our clients, from discovery to clinical validation, by allowing the creation of human interpretable clinically relevant models for patient stratification, selection and diagnosis.

15:50 | Kairo 1+2

### **SOPHIA GENETICS SA**



Global leader in Data-Driven Medicine, SOPHiA GENETICS is a health tech company which has developed SOPHiA AI. Over 400 healthcare institutions in 60 countries use SOPHiA AI daily to rapidly detect and characterize disease-causing genomic alterations. Our innovative approach and global impact have been recognized by the MIT Technology Review who listed SOPHiA GENETICS amongst the 50 Smartest Companies in 2017 and by Fast Company as one of the most innovative biotech in 2018.

16:10 | Kairo 1+2

### SynDermix AG



SynDermix is a Swiss clinical-stage biotech company funded by private investors. We identify and acquire the rights to innovative products of natural origin that satisfy unmet healthcare needs and wellcare demands. We develop the products in our portfolio to strengthen their innovation value until a robust demonstration of their clinical potential and then we enter into corporate partnerships for market access.

14:35 | Kairo 1+2

### Therachon AG



Therachon is a clinical-stage global biotechnology company focused on developing medicines for rare diseases with significant unmet need. The company's lead pipeline candidate, TA-46, is a novel protein therapy in development for achondroplasia, the most common form of short-limbed dwarfism. Therachon is committed to translating the promise of its science into new treatments for patients with high unmet medical needs. Therachon is headquartered in Basel, with research facilities in Nice, France.

14:05 | Kairo 1+2

### **TOPADUR PHARMA AG**



TOPADUR develops innovative drugs for wound healing focusing on specialty high revenue medication. The development candidates are extraordinary products with breakthrough potential to enable healing of chronic wounds in diabetic patients. The medical need for effective therapies for diabetic foot ulcers is huge with annual cost exceeding 13 BN USD. TOP-N53 strongly stimulates local blood flow without causing systemic side effects. First in human studies will start 2018.

### Vaxxilon AG V∧XXILON

Vaxxilon (Basel-area, Berlin) was founded in 2015 to research and develop synthetical carbohydrate vaccines targeting bacterial pathogens. Vaxxilon has completed two proof of concept projects and is advancing several candidates including vaccines to target carbapenem resistant Klebsiella pneumoniae, Clostridium difficile, and Streptococcus pneumoniae. Synthetic vaccines are faster to create and less expensive to produce than traditional conjugate vaccines.

13:55 | Kairo 1+2

## Sponsors

### Cognite

cogNite

Cognite is a fast growing, international Strategy and Communications agency, based in London and Zug. We specialise in breakthrough science brands for rare diseases and other areas. Our reputation is for helping clients to achieve success by creating and communicating compelling stories that really resonate with their customers and differentiate their brands. Contact us to find out more about the power of breakthrough storytelling for your brand.

### **KPMG**



KPMG is a leading professional services firm in Switzerland. Through its strong regional presence KPMG is close to you, helping you navigate today's turbulences to find tomorrow's answers. In audit, tax and advisory, KPMG is noted for clear and consistent solutions. KPMGs life sciences experts have a deep understanding of the industry to support companies in challenges around cost & efficiency, valuation & financing or regulatory compliance. kpmg.ch/lifesciences

### OPIS s.r.l.



OPIS provides clinical drug development services and customized e-clinical solutions to pharma, biotech and medical device clients. Its strength lies in its specialized teams who assist clients from A–Z to ensure quality project execution across Europe. To streamline clinical data handling, the fully FDA 21 CRF Part 11 compliant OPIS eclinical suite is developed in close collaboration with the OPIS biometry and clinical operations units. www.opis-europe.it; www.clinical.net.

### SIX Swiss Exchange



SIX Swiss Exchange is one of the most important European stock exchanges. It offers outstanding liquidity in trading of Swiss securities and connects companies from around the world with international investors and trading participants. SIX Swiss Exchange multiplies the locational advantages of the Swiss financial center with firstclass services and is an ideal listing location for companies of every origin, size and sector. www.six-swiss-exchange.com. Dehli

### Switzerland Global Enterprise (S-GE)



On behalf of the Swiss Confederation and the Swiss cantons, Switzerland Global Enterprise (S-GE) promotes exports and investments by helping its clients to realize new potential for their international businesses and thus to strengthen Switzerland as an economic hub. S-GE is the first point of contact for Swiss companies on all questions relating to internationalization, S-GE also supports foreign companies looking at setting-up operations or R&D partnerships in Switzerland. Shanghai 3

### SWITZERLAND INNOVATION



SWITZERLAND INNOVATION offers technology-driven companies the grounds to collaborate with world-leading universities and to use each other's research results for the development of marketable products and services. SWITZERLAND INNOVATION's parks are the ideal location for research-based companies to create their next breakthrough or best-selling product, and reinforce Switzerland as the world's most innovative country. Shanghai 3

# Thanks to our Sponsors!

#### Sponsors:





































































#### Organised by:













#### Supporting Partners:



Departement für Wirtschaft, Soziales und Umwelt des Kantons Basel-Stadt









